Erratum: Deletion of the highly conserved n-Glycan at asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, And results in loss of viral infectivity (PLoS ONE (2014) 9:6 (e101181) DOI: 10.1371/journal.pone.0101181);Deletion of the highly conserved N-Glycan at Asn260 of HIV-1 gp120 affects folding and lysosomal degradation of gp120, and results in loss of viral infectivity

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Mathys, Leen ^a   François, Katrien O ^a   Quandte, Matthias ^b   Braakman, Ineke ^b   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYSTEINE; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; METHIONINE; N GLYCAN; UNCLASSIFIED DRUG; GLYCOPROTEIN GP 160; HIV ENVELOPE PROTEIN GP120 (135-148); PEPTIDE FRAGMENT; PROTEIN BINDING;

ANTIGEN BINDING; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; EMBRYO; GENE DELETION; GENE MUTATION; GENETIC CONSERVATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LYSOSOME; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FOLDING; PROTEIN TARGETING; VIRUS ENVELOPE; VIRUS INFECTIVITY; WILD TYPE; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; ENDOPLASMIC RETICULUM; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PROTEIN CONFORMATION; PROTEIN PROCESSING; PROTEIN TRANSPORT; SITE DIRECTED MUTAGENESIS; VIROLOGY;

ANTIGENS, CD4; CELL LINE; CONSERVED SEQUENCE; ENDOPLASMIC RETICULUM; GOLGI APPARATUS; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; LYSOSOMES; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; PROTEOLYSIS; SEQUENCE DELETION;

EID: 84903388369     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0110202     Document Type: Erratum

References (36)

1. Hu Q, Mahmood N, Shattock RJ (2007) High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization. Virology 368: 145-154. (Pubitemid 47599570)
2. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, et al. (2008) Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82: 638-651.
3. Reitter JN, Means RE, Desrosiers RC (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4: 679-684. (Pubitemid 28274667)
4. Jitsuhara Y, Toyoda T, Itai T, Yamaguchi H (2002) Chaperone-like functions of high-mannose type and complex-type N-glycans and their molecular basis. J Biochem 132: 803-811. (Pubitemid 35408505)
5. H, Holschbach C, Hunsmann G, Schneider J (1988) Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. J Biol Chem 263: 11760-11767.
6. CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382.
7. C, Doores KJ, Dunlop DC, Thaney V, Dwek RA, et al. (2011) The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade. PLoS One 6: e23521.
8. KJ, Bonomelli C, Harvey DJ, Vasiljevic S, Dwek RA, et al. (2010) Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens. Proc Natl Acad Sci U S A 107: 13800-13805.
9. WR, Syu WJ, Du B, Matsuda M, Tan S, et al. (1992) Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 89: 2213-2217.
10. RL, Smith DH, Lasky LA, Theodore TS, Earl PL, et al. (1988) In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J Virol 62: 139-147.
11. CL, Lao S, Montefiori DC, Haynes BF, Sodroski JG, et al. (2012) High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection. J Virol 86: 2153-2164.
12. W, Nie J, Prochnow C, Truong C, Jia Z, et al. (2013) A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology 10: 14.
13. KO, Balzarini J (2011) The highly conserved glycan at asparagine 260 of HIV-1 gp120 is indispensable for viral entry. J Biol Chem 286: 42900-42910.
14. J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, et al. (2006) Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness. J Virol Methods 136: 102-117.
15. K, Dekeersmaeker N, Schrooten Y, Weber J, Schols D, et al. (2009) Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs. J Clin Microbiol 47: 2232-2242.
16. BS, Thayer RM, Vincent KA, Haigwood NL (1991) Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells. Nucleic Acids Res 19: 3979-3986.
17. V, Cherepanov P, Van Laethem K, Hantson A, Van Remoortel B, et al. (2002) env chimeric virus technology for evaluating human immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents Chemother 46: 3954-3962.
18. J, Desai K, Darbyshire J (2005) The development of vaginal microbicides for the prevention of HIV transmission. PLoS Med 2: e142.
19. Laethem K, Schrooten Y, Lemey P, Van Wijngaerden E, De Wit S, et al. (2005) A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. J Virol Methods 123: 25-34. (Pubitemid 39593730)
20. J, Francois KO, Covens K, Van Laethem K, Balzarini J (2008) Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Virology 382: 10-19.
21. RW, Busser E, Moore JP, Lu M, Berkhout B (2004) Evolutionary repair of HIV type 1 gp41 with a kink in the N-terminal helix leads to restoration of the six-helix bundle structure. AIDS Res Hum Retroviruses 20: 742-749.
22. RW, Dankers MM, Busser E, Caffrey M, Moore JP, et al. (2004) Evolution of the HIV-1 envelope glycoproteins with a disulfide bond between gp120 and gp41. Retrovirology 1: 3.
23. A, Zonneveld D, Braakman I (2003) Folding of HIV-1 envelope glycoprotein involves extensive isomerization of disulfide bonds and conformation-dependent leader peptide cleavage. FASEB J 17: 1058-1067.
24. UK, Molbert E, Showe M, Kellenberger E (1970) Form-determining function of the genes required for the assembly of the head of bacteriophage T4. J Mol Biol 49: 99-113.
25. A, Aebi M (2001) Intracellular functions of N-linked glycans. Science 291: 2364-2369.
26. I, Land A, Eggink D, Verkade E, Tuin K, et al. (2009) Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol 83: 368-383.
27. RW, Hsu ST, van Anken E, Liscaljet IM, Dankers M, et al. (2008) Evolution rescues folding of human immunodeficiency virus-1 envelope glycoprotein GP120 lacking a conserved disulfide bond. Mol Biol Cell 19: 4707-4716.
28. RL, Ross EK, Buckler-White AJ, Theodore TS, Martin MA (1989) Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol 63: 3595-3600.
29. Y, Bergeron JJ, Luo L, Ou WJ, Thomas DY, et al. (1996) Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport. Proc Natl Acad Sci U S A 93: 9606-9611.
30. ES, Parodi AJ (2003) Quality control and protein folding in the secretory pathway. Annu Rev Cell Dev Biol 19: 649-676.
31. JP, Willey RL, Lewis GK, Robinson J, Sodroski J (1994) Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol 68: 6836-6847.
32. C, Macovei A, Petrescu S, Branza-Nichita N (2012) Activation of ERAD pathway by human hepatitis B virus modulates viral and subviral particle production. PLoS One 7: e34169.
33. RL, Bonifacino JS, Potts BJ, Martin MA, Klausner RD (1988) Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A 85: 9580-9584.
34. A, Gennero L, Sperber K, Boelaert JR (2001) The anti-HIV-1 activity of chloroquine. J Clin Virol 20: 131-135.
35. G, Sassaroli M, Louie M, Chen H, Stecher VJ, et al. (1996) Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther 18: 1080-1092.
36. PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.